Q4 adjusted EPS of $2.71 missed analysts' $3.37 estimate; revenue increased 10.0% to $16.618 billion; 2026 adjusted EPS guidance $14.37 to $14.57 above estimates

AbbVie reported Q4 2025 adjusted EPS of $2.71, missing analysts' estimate of $3.37, despite a 10.0% increase in revenue to $16.618 billion. The decline in adjusted EPS was attributed to one-time charges and differences between GAAP and adjusted figures. Although the company raised its full-year 2026 adjusted EPS guidance to $14.37-$14.57, the overall sentiment remains bearish due to the EPS miss and declines in oncology and aesthetics segments.